Extended Data Fig. 8: Molecular determinants of rIL-33-mediated dual PDAC control.
From: IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer
a, Tumour volume in skin (subcutaneous (s.c.)) PDACs in vehicle-treated and rIL-33-treated mice with s.c. PDAC alone (single PDAC) or s.c. and pancreatic PDACs (dual PDAC). b, Gating of ILC2s from parabiotic mice with s.c. PDACs in recipients with/without pancreatic PDACs in donors as in Fig. 4f. c, Experimental schema (left), gating (top) and quantification of donor-derived ILC2s in donor pancreatic (bottom left), recipient s.c. PDAC (bottom middle) and blood (bottom right) in parabiotic PDAC mice treated with vehicle, rIL-33 or rIL-25. d, e, Tumour size in rIL-33-treated WT, Il1rl1−/− and Ltbr−/− s.c. PDAC (single) and s.c. + pancreatic (dual) PDAC mice. f, g, Tumour volume in s.c. PDACs in rIL-33-treated littermate Cre-control, Il7rCre/+Ltbfl/fl (f) and Il7rCre/+Rorafl/fl (g) single and dual PDAC mice. h, Gating of ILC2s from parabiotic mice with s.c. PDACs in recipients and pancreatic PDACs in donors treated with or without antibiotics (Abx) as in Fig. 4g. Data collected at 5–9 days (c, blood), 2 (b, c, tumour) and 3–5 (d) weeks post-implantation, pooled from ≥2 independent experiments with n ≥ 3 mice per group with consistent results. n = individual tumours or organs from individual mice analysed separately. Horizontal bars = median. Cre-control littermates = Il7rCre/+Ltb+/+ (f) and Il7rCre/+Rora+/+ (g). P values by two-way ANOVA with Tukey’s multiple comparison test (a), two-tailed Mann-Whitney test (d tumour weight) and two-way ANOVA with Sidak’s multiple comparison test (all else).
